This Could Be the Most Compelling Value Play Before 2026's Economic Shift

Oscar Health (NYSE: OSCR) reported a roughly $129 million quarterly operating loss amid rising medical-loss ratios and had 2.1 million customers as of Q3 2025. Management plans an average 28% rate increase for 2026 and expects to sustain about $12 billion in premium revenue, targeting a return to profitability next year; a 5% net margin on that revenue would imply a P/E below 8 versus a current market cap of $4.43 billion. The expiration of pandemic-era ACA subsidies could reduce enrollment but is framed as a one-time reset while Oscar's tech-driven platform and scale support long-term market-share gains.

Analysis

Market structure: Rising claims and the end of pandemic-era ACA subsidies compress margins across the individual-market cohort but benefit tech-enabled, price-agile players. Oscar (OSCR) can reprice ~28% in 2026 and scale fixed-cost leverage against ~$12bn premium run-rate; incumbents with large employer books (e.g., UNH) suffer headline investor sentiment and higher near-term loss ratios. Expect ~5-10% share reallocation within the individual market toward lower-cost digital platforms over 12–24 months, tightening pricing power for winners and worsening risk pools for slower movers.

Risk assessment: Tail risks include a legislative extension of subsidies (positive for membership but negative for repricing; 30–60 day catalyst), accelerated claims inflation beyond modeled +5–10% for 2026, or state-level regulatory rate caps that block repricing. Near-term (days–weeks) volatility will track subsidy headlines and Q4 claims prints; short-term (3–6 months) depends on premium filings; long-term (12–24 months) is driven by OSCR’s ability to hit ~5% net margin (~$600m net income on $12bn) and maintain member mix. Hidden dependency: adverse selection if price increases push out healthier enrollees, magnifying MLR deterioration.

Trade implications: A concentrated, sized asymmetric bet is warranted — small equity/option exposure to OSCR ahead of 2026 margin proof points, with protective hedges. Pair trades favor long digital/individual insurers vs short traditional managed-care dispersion; monitor implied vols to deploy calendar/LEAP call spreads. Cross-asset: insurer stress may modestly steepen corporate credit spreads for insurers (bps move risk), lift healthcare cost-sensitive hedges in commodities (medical supplies) and increase put demand in options on UNH/peers.

Contrarian angle: The market is over-discounting OSCR’s ability to reprice and gain operating leverage — current $4.4bn market cap implies low expectation; if OSCR nets even 3–5% margin in 2026 the stock should re-rate materially. Consensus misses state-by-state enrollment stickiness and platform-driven expense declines; but beware the opposite risk: repricing could trigger rapid membership contraction and regulatory intervention. Historical analog: 2017 ACA volatility rewarded winners who proved underwriting cycle improvements within 12–18 months; similar timeline applies here.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in OSCR sized as a thematic value/recovery bet; average-in on weakness and scale to 4–5% only if market cap remains < $5.5bn or if company guidance confirms >20% rate increases plus guidance to reach ~$12bn premiums for 2026.
• Hedge the long OSCR with a limited-cost LEAP call spread: buy Jan 2027 OSCR 25% OTM calls and sell Jan 2027 50% OTM calls (size = 50–75% of equity position) to cap upside cost; set a hard stop-loss to trim if OSCR falls >35% from entry or market cap >$7bn without margin guidance.
• Implement a pair trade: long OSCR (2%) vs short UNH (1%) for 6–12 months to capture re-rating risk; cap UNH short to limit exposure and use 3–5% risk stop (UNH move >+12% from entry) given UNH’s scale and potential defensive flows.
• Reduce broad managed-care exposure by 2–4% and redeploy into insurtech/individual-market names; liquidate or trim larger legacy insurer exposure if their next two quarterly claims prints fail to show normalizing MLR (threshold: <loss-ratio improvement of 200bps over two quarters).
• Monitor congressional subsidy vote and state premium filing approvals over the next 30–60 days: cut OSCR exposure by 50% if subsidies are extended or if state regulators limit filed rate increases by >10 percentage points versus company filings.